

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PRECEDEX safely and effectively. See full prescribing information for PRECEDEX.

### Precedex™ (dexmedetomidine hydrochloride) Injection

For intravenous use.

### Precedex™ (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection

Initial U.S. Approval: 1999

#### INDICATIONS AND USAGE

Precedex is a relatively selective  $\alpha_2$ -adrenergic agonist indicated for:

- Sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Administer Precedex by continuous infusion not to exceed 24 hours. (1.1)
- Sedation of non-intubated patients prior to and/or during surgical and other procedures. (1.2)

#### DOSAGE AND ADMINISTRATION

- Individualize and titrate Precedex dosing to desired clinical effect. (2.1)
- Administer Precedex using a controlled infusion device. (2.1)
- Dilute the 200 mcg/2 mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration. (2.4)
- The 80 mcg/20 mL single-use vial, and 200 mcg/50mL and 400 mcg/100 mL single-use bottles, do not require further dilution prior to administration. (2.4)

**For Adult Intensive Care Unit Sedation:** Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour. (2.2)

**For Adult Procedural Sedation:** Generally initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour. (2.2)

**Alternative Doses:** Recommended for patients over 65 years of age and awake fiberoptic intubation patients. (2.2)

#### DOSAGE FORMS AND STRENGTHS

Precedex Injection, 200 mcg/2 mL (100 mcg/mL) in a glass vial. To be used after dilution. (3)  
Precedex in 0.9% Sodium Chloride Injection 80 mcg/20 mL (4 mcg/mL) in a 20 mL glass vial. Ready to use. (3)  
Precedex in 0.9% Sodium Chloride Injection 200 mcg/50 mL (4 mcg/mL) in a 50 mL glass bottle. Ready to use. (3)  
Precedex in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) in a 100 mL glass bottle. Ready to use. (3)

#### CONTRAINDICATIONS

None. (4)

#### WARNINGS AND PRECAUTIONS

- Monitoring: Continuously monitor patients while receiving Precedex. (5.1)
- Bradycardia and Sinus Arrest: Have occurred in young healthy volunteers with high vagal tone or with different routes of administration, e.g., rapid intravenous or bolus administration. (5.2)
- Hypotension and Bradycardia: May necessitate medical intervention. May be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension, and in the elderly. Use with caution in patients with advanced heart block or severe ventricular dysfunction. (5.2)
- Co-administration with Other Vasodilators or Negative Chronotropic Agents: Use with caution due to additive pharmacodynamic effects. (5.2)
- Transient Hypertension: Observed primarily during the loading dose. Consider reduction in loading infusion rate. (5.3)
- Arousability: Patients can become aroused/alert with stimulation; this alone should not be considered as lack of efficacy. (5.4)
- Prolonged exposure to dexmedetomidine beyond 24 hours may be associated with tolerance and tachyphylaxis and a dose-related increase in adverse events. (5.6)

#### ADVERSE REACTIONS

- The most common adverse reactions (incidence greater than 2%) are hypotension, bradycardia, and dry mouth. (6.1)
- Adverse reactions associated with infusions greater than 24 hours in duration include ARDS, respiratory failure, and agitation. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

#### DRUG INTERACTIONS

Anesthetics, Sedatives, Hypnotics, Opioids: Enhancement of pharmacodynamic effects. Reduction in dosage of Precedex or the concomitant medication may be required. (7.1)

#### USE IN SPECIFIC POPULATIONS

- Geriatric Patients: Dose reduction should be considered. (2.2, 2.3, 5.1, 8.5)
- Hepatic Impairment: Dose reduction should be considered. (2.1, 2.2, 2.3, 5.7, 8.6)
- Pregnancy: Based on animal data, may cause fetal harm. (8.1)
- Nursing Mothers: Caution should be exercised when administered to a nursing woman. (8.3)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 3/2016

## FULL PRESCRIBING INFORMATION: CONTENTS\*

### 1 INDICATIONS AND USAGE

- 1.1 Intensive Care Unit Sedation
- 1.2 Procedural Sedation

### 2 DOSAGE AND ADMINISTRATION

- 2.1 Dosing Guidelines
- 2.2 Dosage Information
- 2.3 Dosage Adjustment
- 2.4 Preparation of Solution
- 2.5 Administration with Other Fluids
- 2.6 Compatibility with Natural Rubber

### 3 DOSAGE FORMS AND STRENGTHS

### 4 CONTRAINDICATIONS

### 5 WARNINGS AND PRECAUTIONS

- 5.1 Drug Administration
- 5.2 Hypotension, Bradycardia, and Sinus Arrest
- 5.3 Transient Hypertension
- 5.4 Arousability
- 5.5 Withdrawal
- 5.6 Tolerance and Tachyphylaxis
- 5.7 Hepatic Impairment

### 6 ADVERSE REACTIONS

- 6.1 Clinical Studies Experience
- 6.2 Postmarketing Experience

### 7 DRUG INTERACTIONS

- 7.1 Anesthetics, Sedatives, Hypnotics, Opioids
- 7.2 Neuromuscular Blockers

### 8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Labor and Delivery
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Hepatic Impairment

### 9 DRUG ABUSE AND DEPENDENCE

- 9.1 Controlled Substance
- 9.3 Dependence

### 10 OVERDOSAGE

### 11 DESCRIPTION

### 12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

### 13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Pharmacology and/or Toxicology

### 14 CLINICAL STUDIES

- 14.1 Intensive Care Unit Sedation
- 14.2 Procedural Sedation

### 16 HOW SUPPLIED/STORAGE AND HANDLING

### 17 PATIENT COUNSELING INFORMATION

\* Sections or subsections omitted from the full prescribing information are not listed.

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

#### **1.1 Intensive Care Unit Sedation**

Precedex™ is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Precedex should be administered by continuous infusion not to exceed 24 hours.

Precedex has been continuously infused in mechanically ventilated patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue Precedex prior to extubation.

#### **1.2 Procedural Sedation**

Precedex is indicated for sedation of non-intubated patients prior to and/or during surgical and other procedures.

### **2 DOSAGE AND ADMINISTRATION**

#### **2.1 Dosing Guidelines**

- Precedex dosing should be individualized and titrated to desired clinical response.
- Precedex is not indicated for infusions lasting longer than 24 hours.
- Precedex should be administered using a controlled infusion device.

## 2.2 Dosage Information

**Table 1: Dosage Information**

INDICATION	DOSAGE AND ADMINISTRATION
<b>Initiation of Intensive Care Unit Sedation</b>	<b>For adult patients:</b> a loading infusion of one mcg/kg over 10 <b>minutes</b> . <b>For adult patients being converted from alternate sedative therapy:</b> a loading dose may not be required [ <i>see Dosage and Administration (2.2)</i> ]. <b>For patients over 65 years of age:</b> a dose reduction should be considered [ <i>see Use in Specific Populations (8.5)</i> ]. <b>For adult patients with impaired hepatic-function:</b> a dose reduction should be considered [ <i>see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)</i> ].
<b>Maintenance of Intensive Care Unit Sedation</b>	<b>For adult patients:</b> a maintenance infusion of 0.2 to 0.7 mcg/kg/hour. The rate of the maintenance infusion should be adjusted to achieve the desired level of sedation. <b>For patients over 65 years of age:</b> a dose reduction should be considered [ <i>see Use in Specific Populations (8.5)</i> ]. <b>For adult patients with impaired hepatic function:</b> a dose reduction should be considered [ <i>see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)</i> ].
<b>Initiation of Procedural Sedation</b>	<b>For adult patients:</b> a loading infusion of one mcg/kg over 10 <b>minutes</b> . For less invasive procedures such as ophthalmic surgery, a loading infusion of 0.5 mcg/kg given over 10 <b>minutes</b> may be suitable. <b>For awake fiberoptic intubation in adult patients:</b> a loading infusion of one mcg/kg over 10 <b>minutes</b> . <b>For patients over 65 years of age:</b> a loading infusion of 0.5 mcg/kg over 10 <b>minutes</b> [ <i>see Use in Specific Populations (8.5)</i> ]. <b>For adult patients with impaired hepatic function:</b> a dose reduction should be considered [ <i>see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)</i> ].
<b>Maintenance of Procedural Sedation</b>	<b>For adult patients:</b> the maintenance infusion is generally initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour. The rate of the maintenance infusion should be adjusted to achieve the targeted level of sedation. <b>For awake fiberoptic intubation in adult patients:</b> a maintenance infusion of 0.7 mcg/kg/hour is recommended until the endotracheal tube is secured. <b>For patients over 65 years of age:</b> a dose reduction should be considered [ <i>see Use in Specific Populations (8.5)</i> ]. <b>For adult patients with impaired hepatic function:</b> a dose reduction should be considered [ <i>see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)</i> ].

## 2.3 Dosage Adjustment

Due to possible pharmacodynamic interactions, a reduction in dosage of Precedex or other concomitant anesthetics, sedatives, hypnotics or opioids may be required when co-administered [*see Drug Interactions (7.1)*].

Dosage reductions may need to be considered for **adult** patients with hepatic impairment, and geriatric patients [*see Warnings and Precautions (5.7), Use in Specific Populations (8.6), Clinical Pharmacology (12.3)*].

## 2.4 Preparation of Solution

Strict aseptic technique must always be maintained during handling of Precedex.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

### **Precedex Injection, 200 mcg/2 mL (100 mcg/mL)**

Precedex must be diluted with 0.9% sodium chloride injection to achieve required concentration (4 mcg/mL) prior to administration. Preparation of solutions is the same, whether for the loading dose or maintenance infusion.

To prepare the infusion, withdraw 2 mL of Precedex Injection, and add to 48 mL of 0.9% sodium chloride injection to a total of 50 mL. Shake gently to mix well.

### **Precedex in 0.9% Sodium Chloride Injection, 80 mcg/20 mL (4 mcg/mL), 200 mcg/50 mL (4 mcg/mL) and 400 mcg/100 mL (4 mcg/mL)**

Precedex in 0.9% Sodium Chloride Injection is supplied in glass containers containing a premixed, ready to use dexmedetomidine hydrochloride solution in 0.9% sodium chloride in water. No further dilution of these preparations are necessary.

## **2.5 Administration with Other Fluids**

Precedex infusion should not be co-administered through the same intravenous catheter with blood or plasma because physical compatibility has not been established.

Precedex has been shown to be incompatible when administered with the following drugs: amphotericin B, diazepam.

Precedex has been shown to be compatible when administered with the following intravenous fluids:

- 0.9% sodium chloride in water
- 5% dextrose in water
- 20% mannitol
- Lactated Ringer's solution
- 100 mg/mL magnesium sulfate solution
- 0.3% potassium chloride solution

## **2.6 Compatibility with Natural Rubber**

Compatibility studies have demonstrated the potential for absorption of Precedex to some types of natural rubber. Although Precedex is dosed to effect, it is advisable to use administration components made with synthetic or coated natural rubber gaskets.

## **3 DOSAGE FORMS AND STRENGTHS**

### **Precedex Injection**

Precedex Injection, 200 mcg/2 mL dexmedetomidine (100 mcg/mL) in a glass vial. To be used after dilution.

### **Precedex in 0.9% Sodium Chloride Injection**

Precedex Injection, 80 mcg dexmedetomidine/20 mL (4 mcg/mL) dexmedetomidine in a 20 mL glass vial. Ready to use.

Precedex Injection, 200 mcg dexmedetomidine/50 mL (4 mcg/mL) dexmedetomidine in a 50 mL glass bottle. Ready to use.

Precedex Injection, 400 mcg dexmedetomidine/100 mL (4 mcg/mL) dexmedetomidine in a 100 mL glass bottle. Ready to use.

## 4 CONTRAINDICATIONS

None

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Drug Administration

Precedex should be administered only by persons skilled in the management of patients in the intensive care or operating room setting. Due to the known pharmacological effects of Precedex, patients should be continuously monitored while receiving Precedex.

### 5.2 Hypotension, Bradycardia, and Sinus Arrest

Clinically significant episodes of bradycardia and sinus arrest have been reported with Precedex administration in young, healthy adult volunteers with high vagal tone or with different routes of administration including rapid intravenous or bolus administration.

Reports of hypotension and bradycardia have been associated with Precedex infusion. Some of these cases have resulted in fatalities. If medical intervention is required, treatment may include decreasing or stopping the infusion of Precedex, increasing the rate of intravenous fluid administration, elevation of the lower extremities, and use of pressor agents. Because Precedex has the potential to augment bradycardia induced by vagal stimuli, clinicians should be prepared to intervene. The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. In clinical trials, glycopyrrolate or atropine were effective in the treatment of most episodes of Precedex-induced bradycardia. However, in some patients with significant cardiovascular dysfunction, more advanced resuscitative measures were required.

Caution should be exercised when administering Precedex to patients with advanced heart block and/or severe ventricular dysfunction. Because Precedex decreases sympathetic nervous system activity, hypotension and/or bradycardia may be expected to be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension and in elderly patients.

In clinical trials where other vasodilators or negative chronotropic agents were co-administered with Precedex an additive pharmacodynamic effect was not observed. Nonetheless, caution should be used when such agents are administered concomitantly with Precedex.

### 5.3 Transient Hypertension

Transient hypertension has been observed primarily during the loading dose in association with the initial peripheral vasoconstrictive effects of Precedex. Treatment of the transient hypertension has generally not been necessary, although reduction of the loading infusion rate may be desirable.

### 5.4 Arousability

Some patients receiving Precedex have been observed to be arousable and alert when stimulated. This alone should not be considered as evidence of lack of efficacy in the absence of other clinical signs and symptoms.

### 5.5 Withdrawal

#### Intensive Care Unit Sedation

With administration up to 7 days, regardless of dose, 12 (5%) Precedex adult subjects experienced at least 1 event related to withdrawal within the first 24 hours after discontinuing study drug and 7 (3%) Precedex adult subjects experienced at least 1 event 24 to 48 hours after end of study drug. The most common events were nausea, vomiting, and agitation.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.